Analysis · UK
Medical Cannabis in Hospital Should Not Depend on Your Postcode
Devon’s new inpatient procedure is welcome, but Cornwall already had a public pathway. The real story is why the NHS still lacks a consistent national standard.
Independent · UK · Patient-first
Medical cannabis,
covered properly.
Clear reporting, useful tools and straight answers for patients navigating a system that is still harder than it should be.
The lead
Analysis · Global
THC and CBD for Dementia Agitation: What the LiBBY Trial Actually Found
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Read the story
New reporting
All stories Latest
Analysis · UK
The UK’s Medical Cannabis Review Is Due. Here Is What It Must Answer
The Government said the ACMD’s review of medical-cannabis legislation was expected in summer 2026. As publication is awaited, these are the tests that should define its value.
Analysis · UK
What One Fire Service’s Drug-Testing Policy Gets Right
An Essex fire-service disclosure offers a rare look inside a safety-critical drug-testing policy—and shows why a positive result should begin a medical review, not end one.
Patient desk
Practical help, without the sales pitch.
Independent tools to help you understand eligibility, compare providers and explore prescribed products.
See all patient toolsCloser to home
All UK reporting United Kingdom
Analysis · UK
Can CBD Oil Trigger a Drug Test? What the Evidence Actually Says
A new systematic review finds that pure CBD is not the main problem. Undeclared THC, inconsistent products and blunt testing policies are where the real risk sits.
Analysis · UK
Medical cannabis and driving: why the UK’s THC rules face scrutiny
Medical cannabis patients can face uncertainty because THC may remain detectable after impairment has passed. The law provides a medical defence, but patients and clinicians continue to call for clearer, evidence-led rules.
Review · UK
Storz & Bickel Mighty+ Review: The Medical Cannabis Vaporiser UK Clinics Actually Recommend
The Mighty+ is the closest thing UK medical cannabis has to a reference vaporiser. We break down what makes it the clinic standard — and whether the £300 price tag is justified for patients.
Beyond Britain
Global reporting Europe, USA & Global
Analysis · Global
Brazil’s New Medical Cannabis Rules Choose Access With Conditions
Brazil’s regulator has clarified a revised pathway for manufacturing and importing medical cannabis products. The model protects access, but keeps the category deliberately temporary.
Analysis · Global
The RESONANCE Trial Asks a Better Question About Cannabis and Cancer
A newly published trial protocol will test whether medicinal cannabis improves quality of life and symptom control in advanced cancer. It is promising research, not a result.
Analysis · Europe
Europe Turns Green: How EU Cannabis Reform Momentum Is Reshaping the Continent
From German pilot programmes to Czech legalisation and French medical trials, European cannabis reform is accelerating. We examine the patchwork of policies reshaping access across the continent.
Patient access
Could medical cannabis be an option?
Prescription cannabis has been legal in the UK since 2018, but access remains confusing. Our two-minute guide explains the criteria and what happens next.
Check your eligibility Private and informational — not a diagnosis.